biotech investing argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
biotech investing argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
biotech investing Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
biotech investing Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
biotech investing argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
biotech investing Cizzle Brands® Corporation Announces Multi-Year Agreement with MLSE to Make CWENCH Hydration the Official Sports Drink of the Toronto Maple Leafs®
biotech investing Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
biotech investing argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
biotech investing Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 14
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for October 13th - 15th
